Literature DB >> 32016001

Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?

Cesare Gridelli1, Assunta Sgambato1.   

Abstract

Entities:  

Year:  2019        PMID： 32016001      PMCID： PMC6976439          DOI： 10.21037/atm.2019.12.31

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  13 in total

Review 1.  FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.

Authors:  Shanthi Marur; Harpreet Singh; Pallavi Mishra-Kalyani; Erin Larkins; Patricia Keegan; Rajeshwari Sridhara; Gideon M Blumenthal; Richard Pazdur
Journal:  Semin Oncol       Date:  2018-10-31       Impact factor: 4.929

2.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

3.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Kristel Vandormael; Antonio Riccio; Jing Yang; M Catherine Pietanza; Julie R Brahmer
Journal:  J Clin Oncol       Date:  2019-01-08       Impact factor: 44.544

Review 4.  Participation of the elderly population in clinical trials: barriers and solutions.

Authors:  Aaron C Denson; Amit Mahipal
Journal:  Cancer Control       Date:  2014-07       Impact factor: 3.302

5.  Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.

Authors:  Kaname Nosaki; Hideo Saka; Yukio Hosomi; Paul Baas; Gilberto de Castro; Martin Reck; Yi-Long Wu; Julie R Brahmer; Enriqueta Felip; Takeshi Sawada; Kazuo Noguchi; Shi Rong Han; Bilal Piperdi; Debra A Kush; Gilberto Lopes
Journal:  Lung Cancer       Date:  2019-07-08       Impact factor: 5.705

6.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

7.  Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).

Authors:  David R Spigel; Michael McCleod; Robert M Jotte; Lawrence Einhorn; Leora Horn; David M Waterhouse; Ben Creelan; Sunil Babu; Natasha B Leighl; Jason C Chandler; Felix Couture; George Keogh; Glenwood Goss; Davey B Daniel; Edward B Garon; Lee S Schwartzberg; Rohini Sen; Beata Korytowsky; Ang Li; Nivedita Aanur; Maen A Hussein
Journal:  J Thorac Oncol       Date:  2019-05-20       Impact factor: 15.609

8.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors:  Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal:  Lancet       Date:  2015-12-19       Impact factor: 79.321

9.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Authors:  Hossein Borghaei; Luis Paz-Ares; Leora Horn; David R Spigel; Martin Steins; Neal E Ready; Laura Q Chow; Everett E Vokes; Enriqueta Felip; Esther Holgado; Fabrice Barlesi; Martin Kohlhäufl; Oscar Arrieta; Marco Angelo Burgio; Jérôme Fayette; Hervé Lena; Elena Poddubskaya; David E Gerber; Scott N Gettinger; Charles M Rudin; Naiyer Rizvi; Lucio Crinò; George R Blumenschein; Scott J Antonia; Cécile Dorange; Christopher T Harbison; Friedrich Graf Finckenstein; Julie R Brahmer
Journal:  N Engl J Med       Date:  2015-09-27       Impact factor: 91.245

10.  Comparison of Immune Checkpoint Inhibitors between Older and Younger Patients with Advanced or Metastatic Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Leyin Zhang; Leitao Sun; Jieru Yu; Feiyu Shan; Kai Zhang; Xi Pang; Chenghao Ma; Yinan Zhang; Minhe Shen; Shenglin Ma; Shanming Ruan
Journal:  Biomed Res Int       Date:  2019-05-13       Impact factor: 3.411
View more
  1 in total

Review 1.  Narrative review of immunotherapy and radiation therapy in elderly patients.

Authors:  Brittney Chau; Jonnby LaGuardia; Caressa Hui; Linda Ye; Yan Xing; Erminia Massarelli; Arya Amini
Journal:  Transl Cancer Res       Date:  2021-05       Impact factor: 1.241
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.